Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

Elias Jabbour, Jorge Cortes, Fabio P.S. Santos, Dan Jones, Susan O'Brien, Gabriela Rondon, Uday Popat, Sergio Giralt, Partow Kebriaei, Roy B. Jones, Hagop Kantarjian, Richard Champlin, Marcos De Lima

Research output: Contribution to journalArticle

Abstract

Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the outcomes of imatinib-resistant CML patients (chronic phase, n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-ABL1 sequencing. Mutations were found in 19 patients (40%); 15 of 19 had advanced CML (AP + BP + second chronic phase). Patients with mutations were more likely to transform toAP/BPat time of imatinib failure (69% vs 35%, P = .03). Forty-two patients (89%) responded to HSCT: 32 (68%) had at least a major molecular response. The 2-year event-free survival was 36% and 58% (P = .05) for the mutant and nonmutant groups, respectively; and the 2-year overall survival was 44% and 76% (P = .02), respectively. HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations. Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI.

Original languageEnglish (US)
Pages (from-to)3641-3647
Number of pages7
JournalBlood
Volume117
Issue number13
DOIs
StatePublished - Mar 31 2011
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem cells
Protein-Tyrosine Kinases
Phosphotransferases
Mutation
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Salvaging
Point Mutation
Disease-Free Survival
Survival

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. / Jabbour, Elias; Cortes, Jorge; Santos, Fabio P.S.; Jones, Dan; O'Brien, Susan; Rondon, Gabriela; Popat, Uday; Giralt, Sergio; Kebriaei, Partow; Jones, Roy B.; Kantarjian, Hagop; Champlin, Richard; De Lima, Marcos.

In: Blood, Vol. 117, No. 13, 31.03.2011, p. 3641-3647.

Research output: Contribution to journalArticle

Jabbour, E, Cortes, J, Santos, FPS, Jones, D, O'Brien, S, Rondon, G, Popat, U, Giralt, S, Kebriaei, P, Jones, RB, Kantarjian, H, Champlin, R & De Lima, M 2011, 'Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations', Blood, vol. 117, no. 13, pp. 3641-3647. https://doi.org/10.1182/blood-2010-08-302679
Jabbour, Elias ; Cortes, Jorge ; Santos, Fabio P.S. ; Jones, Dan ; O'Brien, Susan ; Rondon, Gabriela ; Popat, Uday ; Giralt, Sergio ; Kebriaei, Partow ; Jones, Roy B. ; Kantarjian, Hagop ; Champlin, Richard ; De Lima, Marcos. / Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. In: Blood. 2011 ; Vol. 117, No. 13. pp. 3641-3647.
@article{5cd8ac1881484ef489bf7ff0612541e4,
title = "Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations",
abstract = "Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the outcomes of imatinib-resistant CML patients (chronic phase, n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-ABL1 sequencing. Mutations were found in 19 patients (40{\%}); 15 of 19 had advanced CML (AP + BP + second chronic phase). Patients with mutations were more likely to transform toAP/BPat time of imatinib failure (69{\%} vs 35{\%}, P = .03). Forty-two patients (89{\%}) responded to HSCT: 32 (68{\%}) had at least a major molecular response. The 2-year event-free survival was 36{\%} and 58{\%} (P = .05) for the mutant and nonmutant groups, respectively; and the 2-year overall survival was 44{\%} and 76{\%} (P = .02), respectively. HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations. Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI.",
author = "Elias Jabbour and Jorge Cortes and Santos, {Fabio P.S.} and Dan Jones and Susan O'Brien and Gabriela Rondon and Uday Popat and Sergio Giralt and Partow Kebriaei and Jones, {Roy B.} and Hagop Kantarjian and Richard Champlin and {De Lima}, Marcos",
year = "2011",
month = "3",
day = "31",
doi = "10.1182/blood-2010-08-302679",
language = "English (US)",
volume = "117",
pages = "3641--3647",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Santos, Fabio P.S.

AU - Jones, Dan

AU - O'Brien, Susan

AU - Rondon, Gabriela

AU - Popat, Uday

AU - Giralt, Sergio

AU - Kebriaei, Partow

AU - Jones, Roy B.

AU - Kantarjian, Hagop

AU - Champlin, Richard

AU - De Lima, Marcos

PY - 2011/3/31

Y1 - 2011/3/31

N2 - Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the outcomes of imatinib-resistant CML patients (chronic phase, n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-ABL1 sequencing. Mutations were found in 19 patients (40%); 15 of 19 had advanced CML (AP + BP + second chronic phase). Patients with mutations were more likely to transform toAP/BPat time of imatinib failure (69% vs 35%, P = .03). Forty-two patients (89%) responded to HSCT: 32 (68%) had at least a major molecular response. The 2-year event-free survival was 36% and 58% (P = .05) for the mutant and nonmutant groups, respectively; and the 2-year overall survival was 44% and 76% (P = .02), respectively. HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations. Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI.

AB - Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the outcomes of imatinib-resistant CML patients (chronic phase, n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-ABL1 sequencing. Mutations were found in 19 patients (40%); 15 of 19 had advanced CML (AP + BP + second chronic phase). Patients with mutations were more likely to transform toAP/BPat time of imatinib failure (69% vs 35%, P = .03). Forty-two patients (89%) responded to HSCT: 32 (68%) had at least a major molecular response. The 2-year event-free survival was 36% and 58% (P = .05) for the mutant and nonmutant groups, respectively; and the 2-year overall survival was 44% and 76% (P = .02), respectively. HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations. Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI.

UR - http://www.scopus.com/inward/record.url?scp=79953689908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953689908&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-08-302679

DO - 10.1182/blood-2010-08-302679

M3 - Article

C2 - 21156844

AN - SCOPUS:79953689908

VL - 117

SP - 3641

EP - 3647

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -